FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer

Stefan N Symeonides, Stephen M Anderton, Alan Serrels

Research output: Contribution to journalArticlepeer-review

Abstract

Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further supports the use of FAK inhibitors in combination with immunotherapy.

Original languageEnglish
Pages (from-to)17
JournalJournal for immunotherapy of cancer
Volume5
DOIs
Publication statusPublished - 21 Feb 2017

Keywords

  • FAK
  • Immunotherapy
  • Checkpoint Blockade
  • Pancreatic Cancer

Fingerprint

Dive into the research topics of 'FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this